Literature DB >> 28819938

See and treat strategy by LEEP conization in patients with abnormal cervical cytology.

Fuat Demirkiran, Ilker Kahramanoglu1, Hasan Turan, Nevin Yilmaz, Aslihan Yurtkal, Elif Meseci, Tugan Bese, Sennur Ilvan, Macit Arvas.   

Abstract

OBJECTIVES: To determine the overtreatment and re-LEEP rates of see and treat strategy (S & T) in women who underwent S & T by LEEP and to identify the risk factors for overtreatment and surgical margin and/or endocervical curettage positivity.
MATERIAL AND METHODS: A total of 800 patients who underwent S & T in Istanbul University Cerrahpasa Medical Faculty between June 2010 and June 2016 were retrospectively analyzed.
RESULTS: Overtreatment rate was found to be 46.6%, decreasing with higher grade of cervical smear abnormalities. Age more than 45, low grade of cervical cytologic abnormality and absence of glandular involvement were associated with higher overtreatment rates. The more advanced the histopathology, the more increased risk of surgical margin on LEEP and ECC positivity (p < 0.0001, for both). Glandular involvement was associated with both surgical margin and ECC positivity.
CONCLUSIONS: S &amp; T can be used in patients with high grade cytologic anomaly with an acceptable overtreatment rate. In addition, bigger pieces of specimens may need to be removed during LEEP in patients who have suspicious images of higher grade of abnormalities on colposcopy to reduce surgical margin or ECC positivity. When high rate of ECC positivity in patients with HSIL cytology is considered, we suggest performing ECC to every patients with HSIL.

Entities:  

Keywords:  cervical intraepithelial neoplasia; conization; smear

Mesh:

Year:  2017        PMID: 28819938     DOI: 10.5603/GP.a2017.0066

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  1 in total

1.  Construction and Evaluation of a Clinical Prediction Scoring System for Positive Cervical Margins Under Colposcopy.

Authors:  Meiling Zhu; Mingyue Yu; Zhengzheng Chen; Weidong Zhao
Journal:  Front Med (Lausanne)       Date:  2022-02-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.